Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.59 |
| ▸ | F2 | P00734 | 12/20 | 0.59 |
| ▸ | PLG | P00747 | 1/20 | 0.56 |
| ▸ | PLAT | P00750 | 1/20 | 0.56 |
| ▸ | PROC | P04070 | 1/20 | 0.56 |
| ▸ | KLK6 | Q92876 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7215947 | 0.91 | F10 (0.64) | F10F2PLGPLATPROC | |
| Trifluoroacetic Acid SCHEMBL7219682 | 0.91 | F10 (0.64) | F10F2PLGPLATPROC | |
| Trifluoroacetic Acid SCHEMBL7378773 | 0.87 | F10 (0.62) | F10F2PLGPLATPROC | |
| Trifluoroacetic Acid SCHEMBL2329447 | 0.82 | F10 (0.68) | F10F2PLGPLATPROC | |
| Trifluoroacetic Acid SCHEMBL2329444 | 0.82 | F10 (0.68) | F10F2PLGPLATPROC | |
| Trifluoroacetic Acid SCHEMBL7382209 | 0.82 | F10 (0.61) | F10F2PLGPLATPROC | |
| Trifluoroacetic Acid SCHEMBL7543477 | 0.81 | F10 (0.69) | F10F2PLGPROC | |
| Trifluoroacetic Acid SCHEMBL2328333 | 0.79 | F10 (0.89) | F10F2PLGPLATPROC | |
| Trifluoroacetic Acid SCHEMBL2328337 | 0.79 | F10 (0.89) | F10F2PLGPLATPROC | |
| SCHEMBL7550978 | 0.78 | F10 (0.68) | F10F2PLGPLATPROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0944386-B1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2002-09-18 | — | — | EP | claimed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | claimed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | STS, ARSA, F12 | F10 20/4885F2 11/4885PLG 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.